文献速递白血病

砷剂联合全反式维甲酸不化疗治疗急性早幼粒细胞白血病的长期真实世界结局:一项回顾性单中心研究

Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study.
PubMed 文献 · Br J Haematol · 2022-12-18

回顾性单中心研究纳入206例急性早幼粒细胞白血病患者,采用三氧化二砷联合全反式维甲酸诱导、巩固,中高危患者加用2年维持治疗,未用化疗。全队列估计5年无事件生存率和总生存率分别为79%和80%;排除7天内死亡者后分别为90%和93%。

要点

  • 全风险组患者采用三氧化二砷联合全反式维甲酸不化疗方案,5年无事件生存率79%、总生存率80%。
  • 排除7天内死亡患者后,5年无事件生存率90%、总生存率93%。
  • 分化综合征发生于41例(19.9%),25例(12.1%)在开始治疗后7天内死亡。

核心结论

  • 在真实世界环境中,全风险组急性早幼粒细胞白血病患者采用三氧化二砷联合全反式维甲酸不化疗方案与优异的长期结局相关。

研究设计与样本

  • 回顾性单中心研究,共纳入206例急性早幼粒细胞白血病患者。
  • 患者接受三氧化二砷联合全反式维甲酸诱导,达形态学缓解后接受3个周期三氧化二砷联合全反式维甲酸巩固(每周期间隔1个月)。
  • 中危和高危患者进一步接受2年维持治疗,方案为全反式维甲酸、6-巯基嘌呤和甲氨蝶呤。

主要发现

  • 中危患者占51.9%,高危患者占43.2%。
  • 41例(19.9%)发生分化综合征,25例(12.1%)在开始治疗后7天内死亡。
  • 随访期间7例患者复发。
  • 全队列估计5年无事件生存率(均值[标准差])为79%[5.8%],总生存率为80%[5.8%]。
  • 排除开始治疗后7天内死亡的患者后,估计5年无事件生存率为90%[5.8%],总生存率为93%[3.9%]。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) form the backbone of the treatment of acute promyelocytic leukaemia (APL), with the addition of chemotherapy for high-risk patients. We describe our experience of treating patients with APL of all risk classes with ATO and ATRA without chemotherapeutic agents. Patients received induction with ATO and ATRA followed by three cycles of consolidation with ATO and ATRA (each 1 month apart) after achieving morphological remission. Patients with intermediate- and high-risk disease received a further 2 years of maintenance with ATRA, 6-mercaptopurine and methotrexate. A total of 206 patients were included in the study. The majority of the patients were intermediate risk (51.9%), followed by high risk (43.2%). Differentiation syndrome was seen in 41 patients (19.9%). Overall, 25 patients (12.1%) died within 7 days of initiating therapy. Seven patients relapsed during follow-up. The mean (SD) estimated 5-year event-free survival (EFS) and overall survival (OS) in the entire cohort was 79% [5.8%] and 80% [5.8%] respectively. After excluding patients who died within 7 days of therapy initiation, the mean (SD) estimated 5-year EFS and OS was 90% [5.8%] and 93% [3.9%] respectively. Our study shows that treatment of all risk classes of APL with ATO and ATRA without chemotherapy is associated with excellent long-term outcomes in the real-world setting.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Singh C, Yanamandra U, Karunakaran P, et al. Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study. Br J Haematol. 2022. PMID: 36529704. doi:10.1111/bjh.18618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。